Literature DB >> 33479690

Structure-property studies of an imidazoquinoline chemotype with antitrypanosomal activity.

Dana M Klug1, Rosario Diaz-Gonzalez2, Travis J DeLano1, Eftychia M Mavrogiannaki1, Melissa J Buskes1, Raeann M Dalton1, John K Fisher1, Katherine M Schneider1, Vivian Hilborne1, Melanie G Fritsche1, Quillon J Simpson1, Westley F Tear1, William G Devine1, Guiomar Pérez-Moreno2, Gloria Ceballos-Pérez2, Raquel García-Hernández2, Cristina Bosch-Navarrete2, Luis Miguel Ruiz-Pérez2, Francisco Gamarro2, Dolores González-Pacanowska2, Maria Santos Martinez-Martinez3, Pilar Manzano-Chinchon3, Miguel Navarro2, Michael P Pollastri1, Lori Ferrins1.   

Abstract

Human African trypanosomiasis is a neglected tropical disease (NTD) that is fatal if left untreated. Although approximately 13 million people live in moderate- to high-risk areas for infection, current treatments are plagued by problems with safety, efficacy, and emerging resistance. In an effort to fill the drug development pipeline for HAT, we have expanded previous work exploring the chemotype represented by the compound NEU-1090, with a particular focus on improvement of absorption, distribution, metabolism and elimination (ADME) properties. These efforts resulted in several compounds with substantially improved aqueous solubility, although these modifications typically resulted in a loss of trypanosomal activity. We herein report the results of our investigation into the antiparasitic activity, toxicity, and ADME properties of this class of compounds in the interest of informing the NTD drug discovery community and avoiding duplication of effort. This journal is © The Royal Society of Chemistry 2020.

Entities:  

Year:  2020        PMID: 33479690      PMCID: PMC7496307          DOI: 10.1039/d0md00103a

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  21 in total

1.  Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery.

Authors:  Travis T Wager; Xinjun Hou; Patrick R Verhoest; Anabella Villalobos
Journal:  ACS Chem Neurosci       Date:  2016-04-04       Impact factor: 4.418

2.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.

Authors:  F S Buckner; C L Verlinde; A C La Flamme; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

3.  In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.

Authors:  Roula Konsoula; Mira Jung
Journal:  Int J Pharm       Date:  2008-05-13       Impact factor: 5.875

4.  Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.

Authors:  Victor Kande Betu Ku Mesu; Wilfried Mutombo Kalonji; Clélia Bardonneau; Olaf Valverde Mordt; Séverine Blesson; François Simon; Sophie Delhomme; Sonja Bernhard; Willy Kuziena; Jean-Pierre Fina Lubaki; Steven Lumeya Vuvu; Pathou Nganzobo Ngima; Hélène Mahenzi Mbembo; Médard Ilunga; Augustin Kasongo Bonama; Josué Amici Heradi; Jean Louis Lumaliza Solomo; Guylain Mandula; Lewis Kaninda Badibabi; Francis Regongbenga Dama; Papy Kavunga Lukula; Digas Ngolo Tete; Crispin Lumbala; Bruno Scherrer; Nathalie Strub-Wourgaft; Antoine Tarral
Journal:  Lancet       Date:  2017-11-04       Impact factor: 79.321

5.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

6.  Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors.

Authors:  Baljinder Singh; Jean A Bernatchez; Laura-Isobel McCall; Claudia M Calvet; Jasmin Ackermann; Julia M Souza; Diane Thomas; Everton M Silva; Kelly A Bachovchin; Dana M Klug; Hitesh B Jalani; Seema Bag; Melissa J Buskes; Susan E Leed; Norma E Roncal; Erica C Penn; Jessey Erath; Ana Rodriguez; Richard J Sciotti; Robert F Campbell; James McKerrow; Jair L Siqueira-Neto; Lori Ferrins; Michael P Pollastri
Journal:  ACS Med Chem Lett       Date:  2020-01-10       Impact factor: 4.345

7.  Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.

Authors:  William Devine; Jennifer L Woodring; Uma Swaminathan; Emanuele Amata; Gautam Patel; Jessey Erath; Norma E Roncal; Patricia J Lee; Susan E Leed; Ana Rodriguez; Kojo Mensa-Wilmot; Richard J Sciotti; Michael P Pollastri
Journal:  J Med Chem       Date:  2015-07-08       Impact factor: 7.446

8.  Anilinoquinoline based inhibitors of trypanosomatid proliferation.

Authors:  Lori Ferrins; Amrita Sharma; Sarah M Thomas; Naimee Mehta; Jessey Erath; Scott Tanghe; Susan E Leed; Ana Rodriguez; Kojo Mensa-Wilmot; Richard J Sciotti; Kirsten Gillingwater; Michael P Pollastri
Journal:  PLoS Negl Trop Dis       Date:  2018-11-26

9.  Establishment of a structure-activity relationship of 1H-imidazo[4,5-c]quinoline-based kinase inhibitor NVP-BEZ235 as a lead for African sleeping sickness.

Authors:  João D Seixas; Sandra A Luengo-Arratta; Rosario Diaz; Manuel Saldivia; Domingo I Rojas-Barros; Pilar Manzano; Silvia Gonzalez; Manuela Berlanga; Terry K Smith; Miguel Navarro; Michael P Pollastri
Journal:  J Med Chem       Date:  2014-05-21       Impact factor: 7.446

10.  Plasmodial Kinase Inhibitors: License to Cure?

Authors:  Diego González Cabrera; André Horatscheck; Colin R Wilson; Greg Basarab; Charles J Eyermann; Kelly Chibale
Journal:  J Med Chem       Date:  2018-06-04       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.